Vaccination status (PCV13) of children with pneumococcal meningitis

Aliya Seidullayeva, Dinagul Bayesheva, Bayan Turdalina, A. V. Altynbekova, A. Omarova, Meruert Khamitova, Sabit Tashenov, Aislu Otarbayeva, Samat Kozhakhmetov

Journal of Clinical Medicine of Kazakhstan, 2020

Full text Open access: Gold Metadata (CSL-JSON)

DOI 10.23950/1812-2892-jcmk-00764

Data confidence 70 medium

How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Pneumococcal meningitis in children is one of the reasons for the development of serious neurological complications. According to various authors, in developed countries, the incidence rate ranges from 8 to 34 cases per 100,000 population, in Kazakhstan there is no etiological interpretation of bacterial meningitis, and therefore there are no official statistics on the incidence. To date, in more than 120 countries, the pneumococcal conjugate vaccine has been added to the vaccination calendar, which is the most effective method for reducing the incidence of bacterial meningitis pneumococcal etiology. This article reflects the effectiveness of vaccination and the risk of bacterial meningitis in children with pneumococcal meningitis in terms of using the PCV13 vaccine.